HealthTech capital members serve for rotating terms on the Screening Committee. These members have experience with the HealthTech stakeholders including business solutions for providers, payers and patients. Our members’ expertise covers Digital Health, Pharmaceuticals & Therapeutics, Medical Device & Instrumentation, Drug Discoveries, Diagnostics and Healthcare Services.
Ben Lenail is very active in the non-profit sector. He is a founding officer of ALD Connect, a research consortium focused on the neuro-metabolic disease X-linked adrenoleukodystrophy (X-ALD). Ben is also on the Executive Committee of Silicon Valley Social Ventures (SV2).
Ben was previously a distinguished visiting scholar at Stanford University, and Senior Director of Corporate Development at Sun Microsystems. Ben has a Bachelor’s from Sciences Po (Paris, France) and an MBA from the University of Washington with a concentration in Finance and Operations Management.
In his free time, Ben enjoys spending time with his family and his beloved Golden Retriever Hazel, cycling, and walking.
Do you charge companies to present?Absolutely not! HTC does not charge application or presentation fees. Because HealthTech Capital provides significant added value to companies, such as leading a term sheet, strategic advice, industry connections, mentoring, board members and board observers, common stock options are expected in exchange for these services.